FORUM Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Registration Number
- NCT02246075
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT02149160
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇮🇹IRCCS - Centro S. Giovanni di Dio FateBeneFratelli, Brescia, Italy
🇮🇹Neurological Clinic, University of Brescia, AO Civil Hospital of Brescia, Brescia, Italy
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT02037074
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 348
- Registration Number
- NCT02004392
Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02001389
EVP-6124 Hepatic Impairment Study
Phase 1
Completed
- Conditions
- Hepatic Impairment
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 34
- Registration Number
- NCT01984736
EVP-6124 Renal Impairment Study
Phase 1
Completed
- Conditions
- Renal Impairment
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01984723
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
Phase 3
Terminated
- Conditions
- DementiaAlzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 403
- Registration Number
- NCT01969136
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Alzheimer's DiseaseDementia
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 474
- Registration Number
- NCT01969123
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 767
- Registration Number
- NCT01716975
© Copyright 2025. All Rights Reserved by MedPath